Arthritis Drug for Treatment of COVID-19

The US Food and Drug Administration (FDA) has approved drug Actemra (tocilizumab), the arthritis drug, for the treatment of hospitalized patients with COVID-19.

The US Food and Drug Administration (FDA) has approved drug Actemra (tocilizumab), used for arthritis, for the treatment of hospitalized patients with COVID-19.

Under the EUA, the drug can be administered only to hospitalised adults and //pediatric patients (2 years of age and older), receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.

‘Actemra, the arthritis drug is not authorized for use in outpatients with COVID-19, the FDA said in a statement. ’

Clinical trials showed that administering Actemra to hospitalised Covid-19, in addition to routine care which included corticosteroid therapy, reduced the risk of death as well as decreased the amount of time patients remained hospitalised.

The risk of patients being placed on ventilators or death was also decreased.

"Although vaccines have been successful in decreasing the number of patients with Covid-19 who require hospitalisation, providing additional therapies for those who do become hospitalised is an important step in combating this pandemic," said Patrizia Cavazzoni, MD, Director of the FDA's Center for Drug Evaluation and Research.

Mucormycosis (Black Fungal Disease): A Complication of COVID-19
Mucormycosis is spread by spores from the black fungus, Mycormycetes. It mainly affects people with a weak immune system and attacks the lungs and other organs of the body. It is also known as Black Fungal Disease.

Actemra is a monoclonal antibody that reduces inflammation and is given by intravenous infusion that is FDA-approved for multiple inflammatory diseases, including rheumatoid arthritis.

In the case of Covid-19 infection, the immune system can become hyperactive, which may result in worsening of disease. But, Actemra does not directly target SARS-COV-2.

Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to spike up with the “second wave” of COVID-19.

With spiking effects of the second wave of coronavirus, the best way to keep it at bay is to follow COVID-appropriate safety practices like wearing a mask, regularly cleaning your hands, and coughing into a bent elbow or tissue along with physical distancing (6 feet about 2 arm's length), that may help evade the severity of COVID-19 infection.

Based on the FDA's review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that Actemra may be effective in treating Covid-19 for the authorised population.

How Exercise Influence the Severe COVID-19 Outcome?
Exercising more than 150 minutes a week is associated with a reduced risk of COVID infection, revealed a new study.

The data supporting this EUA for Actemra are based on four clinical trials. All four clinical trials contribute to the FDA's understanding of Actemra for the treatment of Covid-19.

Common side effects of Actemra observed in the Covid-19 trials include constipation, anxiety, diarrhoea, insomnia, hypertension and nausea. The EUA was issued to American biotechnology Genentech, a subsidiary of Swiss multinational healthcare Roche, FDA said.

Source-IANS